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Pegloticase is a powerful but underutilized weapon in
the rheumatologist’s armamentarium. The drug’s
immunogenicity leads to neutralizing antibody
formation and rapid loss of efficacy in roughly one-half
of all patients, which remains an impediment to broader
use. New data, however, suggest that drug survival
might improve with concomitant immunosuppressive
agent (s), which merits further study. Efficacy appears
to be unchanged when pegloticase is infused at
3-week (rather than 2-week) intervals. Stretching the
time between infusions may also improve patient
adherence and allow for earlier identification of transient
responders.bodies to PEG are not pathogenic [2]. A separate andIn the previous issue of Arthritis Research and Therapy,
Hershfield and colleagues published a study putting forth
a number of novel and potentially important findings re-
garding pegloticase, a powerful but underutilized weapon
in the small but growing anti-hyperuricemic arsenal [1].
The study examined the efficacy of pegloticase in a
cohort of 30 patients with severe gout (93% tophaceous)
utilizing an every 3-week infusion regimen, rather than
the every 2-week schedule employed in previously pub-
lished phase 3 trials. Despite the longer interval between
infusions in the current study, the effectiveness of
pegloticase is no worse (17/30 patients are persistent
responders), and the pharmacokinetics of the drug
suggest this should come as no surprise. The authors
correctly note that a 3-week interval would be signifi-
cantly more convenient for patients, and notably that
such a regimen would also prove less costly to payors.
Hershfield and colleagues’ dosing schedule would also
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2014of treatment – only four of 12 transient responders had
uric acid >6 mg/dl 2 weeks after the first infusion (three of
whom had previously been exposed to pegloticase in
earlier phase 1 and 2 studies), whereas 11 of 12 transient
responders had uric acid >6 mg/dl at 3 weeks (vs. only
one of 17 persistent responders). For the reasons just
elaborated upon, the paper demonstrates that dosing
every 3 weeks may not just be as good as the current
protocol, but may in some ways be superior.
Hershfield and colleagues also upend the assumption
that neutralizing antibodies to pegloticase are formed
against uricase itself. Their paper clearly demonstrates
that neutralizing antibodies develop in response to the
polyethylene glycol (PEG) moiety of the drug, a finding
that rebuffs a recent commentary which suggested anti-
larger study (169 patients exposed to pegloticase) pub-
lished in the previous issue Arthritis Research and Therapy
by Lipsky and colleagues reaches the same conclusion
regarding anti-pegloticase antibodies: anti-PEG antibodies
are responsible for loss of efficacy rather than antibodies
to the uricase enzyme itself, the latter of which rarely
occur (positive more than once in only 11 subjects) and
occur much later during the course of treatment, long
after neutralizing anti-pegloticase antibodies have devel-
oped [3]. This larger study also demonstrates that an anti-
pegloticase antibody titer >1:2,430 generally predicts loss
of efficacy to the drug.
Finally, and not least of all, Hershfield and colleagues’
smaller study included post-transplant patients (who
were excluded from the phase 3 studies), a population
particularly susceptible to developing gout. Of seven
post-transplant subjects in the study, six proved to be
persistent responders (86%) [1]. Although this is an ad-
mittedly small number of patients upon which to base
any conclusion, it does raise the intriguing question of
whether immunosuppression might lead to less of a
mounted antibody response against pegloticase, and thus
to more favorable outcomes. This is no small point;his is an Open Access article distributed under the terms of the Creative
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vere, long-standing, and refractory gout, and should be
given every chance to optimize their response to a po-
tentially transformative therapy.
While this signal is worth pursuing, some questions
are immediately raised: how immunosuppressed must
patients be to prevent neutralizing anti-PEG antibody
formation, and with what should this be accomplished?
Of the small subcohort in this trial, all patients were on
cyclosporine or mycophenolate mofetil, and five of seven
patients were on a combination of immunosuppressive
agents. In choosing an immunosuppressant for the ex-
press purpose of preventing neutralizing antibodies, the
risk of these drugs would very probably outweigh any
proposed benefit (cyclosporine in particular might be
the least desirable immunosuppressant for a patient with
severe gout, because it both increases serum uric acid
levels and decreases the glomerular filtration rate).
If a trial was designed to investigate this line of query,
a reasonable immunosuppressive agent of choice might
be methotrexate. This drug has been shown to effect-
ively prevent neutralizing antibodies from forming
against monoclonal antibodies to anti-tumor necrosis
factor [4,5]. Methotrexate’s inhibitory effect may not ex-
tend to preventing antibody formation against PEG, al-
though methotrexate has also been shown to inhibit
antibody formation against the polysaccharide 23-valent
pneumococcal vaccine [6]. Methotrexate might also yield
the unintended benefit of acting as an anti-inflammatory
agent to suppress gouty attacks. However, because pa-
tients with severe gout have multiple comorbidities that
place them at higher risk for medication side effects,
methotrexate should not be considered in the clinical
setting in the absence of data to support its use [7].
Nevertheless, methotrexate therapy is an avenue of
inquiry that is clinically relevant and needs exploration
to increase the likelihood that patients who begin this
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